Gossamer Bio provides interim TORREY OLE data and PROSERA Phase 3 trial design

Gossamer Bio, Inc.

Announced interim data from open-label extension of seralutinib in PAH patients.
Detailed design of planned Phase 3 PROSERA trial for seralutinib.
No specific efficacy or safety numbers disclosed in the filing or exhibit.
Corporate presentation furnished as Exhibit 99.1 contains the update.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.